Evan Seigerman, an analyst from BMO Capital, maintained the Buy rating on Disc Medicine (IRON – Research Report). The associated price target remains the same with $120.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evan Seigerman’s rating is based on several promising developments within Disc Medicine’s portfolio. The long-term treatment with Bitopertin has shown significant reductions in ALT levels, suggesting potential liver benefits for patients with EPP. Additionally, DISC-0974 has demonstrated durable responses in MF anemia, with some patients maintaining transfusion independence over an extended period.
Moreover, DISC-3405 has shown robust hepcidin induction and substantial serum iron reductions in healthy volunteers, indicating a promising profile for future Phase 2 development. The combination of these positive clinical data points across Disc Medicine’s assets supports the Buy rating, as they highlight the potential for effective treatments for various rare blood disorders. The anticipation of further updates and FDA interactions also contributes to the optimistic outlook for the company’s stock.
IRON’s price has also changed moderately for the past six months – from $64.270 to $52.710, which is a -17.99% drop .